So do I (now). Thx Historian but for some reason the page listed nothing to me for 2 or 3 "clicks". 11 means they added a few right?
I don't know how long you were gone, but on September 4th, they added the top two on the list of openings. I was gone for about 10 days also, so I don't know if any positions were filled during that time.
OK, I found it. It was muscular dystrophy but the authors claim the therapy "represent(s) a paradigm shift for the treatment of muscular dystrophy as well as a host of other disabling and devastating muscle diseases." The title is "Triggering regeneration and tackling apoptosis: a combinatorial approach to treating congenital muscular dystrophy type 1 A," so a google search should pull it up. I wonder if there is any follow-up on this work published in the journal, Human Molecular Genetics in June 2013.
Can someone explain why Insmed has not updated their Analyst Coverage page on their website?
Firm Analyst (Cowen is missing: they initiated coverage about 2 weeks ago)
Canaccord Genuity Ritu Baral (very OLD, she has been with Cowen for more than 3 months)
H.C. Wainwright & Co. Andrew Fein
JMP Securities Liisa Bayko
Leerink Swann Joseph P. Schwartz
Piper Jaffray Joshua Schimmer
UBS Matthew Roden
Hi Rook, I'm not sure who is responsible for keeping the information updated, but I believe that Anne Marie Fields is under contract to serve as IR spokesperson for Insmed whether she receives 1 or 1000 calls so it may make sense to start with her.
IR just replied and the site (Analyst coverage) will be updated as soon as possible. Why not stay current though? Just seems "sloppy" to me.
deleted this morning "Blind Investing "-The mindless rank outs show clear investor ignorance. ( zipRoberts ex below ) - I sent the chart to 8 traders this morning, my short from Jess's Tuesday ! Load up post Sept 8 .......
is up 13% but ....Have more fun!
Hurry before it gets deleted -terry--_insm • Sep 9, 2014 - the same ones again who didn't have a clue Monday and I just about caught the top. Yes I am short"
The intiated coverage of firms is usually disregarded. Besides the targets are at the low end of the spectrum,so who cares about their targets as a long anyway,they`re way to low.
Sentiment: Strong Buy
Well Hubby, I think it's important to ignore the current share price when reflecting on the potential success or failure of Insmed which will determine the share price of the future. If I have read the data correctly, then despite today's low SP, the future share price will reflect the approvals of NTM and CF in Europe, Canada and the ROW. That SP will be many multiples of today's. If I am wrong about the new data (which is now public but never PR'd in an attention-grabbing way), and the old data were to be thrown out (far-fetched), then the current share price is overvalued by several times. The data is the most important piece of information in determining whether Insmed is a buy or sell at this time. It shows that Arikace is the first and only drug to ever show long-term success in FEV-1 for Cystic Fibrosis. This is on top of meeting its primary endpoint last year. The data shows the NTM patients in record numbers became culture-negative, when no other treatment has shown such success in 84 days. I look at today's share price, and I see a "screaming buy."
Sentiment: Strong Buy
I believe that starting next month, we will get a stream of news related to next steps and assorted developments. If I remember correctly, WL said that we would have 4th quarter updates, etc.
jsblvbjb explained why he thought the stock would go up- based on new information from poster at a Presentation.- I didnt even read it, and perhaps there was new data but the presentation was a redo of the one given in San Diego in May.../
I opined that new substantial info wont come from jesse the mb poster but from a material information PR from the company( as it did in May).The tape told the trading part . -
.I have opined and many analysts agree Arikayce for CF, will not bew much,- Novartis is the clear winner. jsblvbjb and I can agree on NTM being Insmed -and that remains to be seen...
The greatest part of Insmed revenues will not be seen until 2018..." "A screaming buy" has turned into a trading profit again with kvncmcdd buying the top yet once again..
- If you are a long term investor buy the dips and dips there will be.-
-Good Luck .
Material information such as new data will be presented in a PR from the company. I posted the chart yesterday and kvncmcdd quickly deleted it, wrong again. guess why ,hes not trading ,he's hyping ,
Its the MACD stupid!
Reply to Tuesday is the big day!!! Load up tomorrow,
kvmncdd • Next Tuesday Im buying a lot!
kvnmcdd • Sep 19, 2014 you got to love it. Trying to add on my cell phone app...rather be at my computer.
It has occurred to me, that with all of the opining going on here, if I offered a "penny for your thoughts", I would want change back from some of the posters opining.
.....will be disseminated tomorrow (Wednesday) after hours. I'm guessing there might be an increase??? Also, I sensed yesterday had a feeling of a higher percentage of shorting? Just a feeling......not opining.
You nailed it. Short sales ratio yesterday was 60.1%. They really piled it on again. It bothers me that the management is so lazy in disseminating material information to its shareholders. I sent a note to IR asking why we have to find out things on a message board instead of through their PR efforts? They didn't bother to respond to that either. They may be good at science but they're lousy at IR and PR.
Sentiment: Strong Buy